Feb 14, 2022 8:00am EST Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures
Feb 09, 2022 6:30pm EST Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021
Feb 01, 2022 4:15pm EST Medexus to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference
Dec 02, 2021 8:08am EST Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac’s Type A Meeting with FDA on Treosulfan
